Theranexus Société Anonyme (EPA:ALTHX)

Market Cap	3.41M
Revenue (ttm)	2.30M
Net Income (ttm)	-1.77M
Shares Out	7.76M
EPS (ttm)	n/a
PE Ratio	n/a
Forward PE	8.98
Dividend	n/a
Ex-Dividend Date	n/a

Volume	59,201
Average Volume	40,066
Open	0.4340
Previous Close	0.4300
Day's Range	0.4200 - 0.4426
52-Week Range	0.2605 - 1.2000
Beta	2.51
RSI	57.47
Earnings Date	Apr 29, 2025

About EPA:ALTHX

Theranexus Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for Batten disease. The company was founded in 2013 and is headquartered in Lyon, France.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 17
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALTHX

Financial Performance

In 2024, EPA:ALTHX's revenue was 2.30 million, an increase of 674.81% compared to the previous year's 296,331. Losses were -1.77 million, -74.15% less than in 2023.